Treatment-Resistant Depression and ketamine research
An educational overview of treatment-resistant depression (TRD), how it is defined, and the current evidence on ketamine and esketamine as adjunctive options.
Overview
Treatment-resistant depression generally describes major depressive disorder that has not adequately responded to at least two trials of evidence-based antidepressants at adequate doses and duration. Exact definitions vary across guidelines.
Conventional treatment
Approaches include optimizing current medications, switching agents, augmenting with another medication, neuromodulation (TMS, ECT), and structured psychotherapy. Comprehensive reassessment of diagnosis, comorbidities, and life context is part of responsible care.
Where ketamine fits
Subanesthetic IV ketamine and FDA-approved intranasal esketamine are studied and used as adjunctive options for TRD in some clinical settings. Programs typically combine dosing with ongoing psychiatric care and integration.
What current evidence suggests
RCTs and real-world studies suggest meaningful symptom reductions for a subset of patients with TRD, often within days. Durability frequently requires maintenance dosing and broader treatment plans.
Frequently asked questions
What defines TRD?+
Most commonly, inadequate response to at least two adequately delivered evidence-based antidepressants. Definitions vary.
Is esketamine the same as ketamine?+
Esketamine is the S-enantiomer of ketamine, FDA-approved for certain depressive conditions as a nasal spray under supervision. Racemic ketamine is also used off-label in many clinics.
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.